These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 1312127)
1. Baculovirus-expressed glycoprotein H of herpes simplex virus type 1 (HSV-1) induces neutralizing antibody and delayed type hypersensitivity responses, but does not protect immunized mice against lethal HSV-1 challenge. Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL J Gen Virol; 1992 Mar; 73 ( Pt 3)():719-22. PubMed ID: 1312127 [TBL] [Abstract][Full Text] [Related]
2. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus. Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412 [TBL] [Abstract][Full Text] [Related]
4. Expression and characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein L. Ghiasi H; Kaiwar R; Slanina S; Nesburn AB; Wechsler SL Arch Virol; 1994; 138(3-4):199-212. PubMed ID: 7998829 [TBL] [Abstract][Full Text] [Related]
5. Cell surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus-infected cells. Ghiasi H; Nesburn AB; Wechsler SL Virology; 1991 Nov; 185(1):187-94. PubMed ID: 1656584 [TBL] [Abstract][Full Text] [Related]
6. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection. Chan WL; Lukig ML; Liew FY J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536 [TBL] [Abstract][Full Text] [Related]
7. Analysis of protective immune responses to the glycoprotein H-glycoprotein L complex of herpes simplex virus type 1. Browne H; Baxter V; Minson T J Gen Virol; 1993 Dec; 74 ( Pt 12)():2813-7. PubMed ID: 8277292 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403 [TBL] [Abstract][Full Text] [Related]
9. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. Martin S; Rouse BT J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075 [TBL] [Abstract][Full Text] [Related]
10. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL J Virol; 1994 Apr; 68(4):2118-26. PubMed ID: 8138996 [TBL] [Abstract][Full Text] [Related]
11. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. Karem KL; Bowen J; Kuklin N; Rouse BT J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066 [TBL] [Abstract][Full Text] [Related]
12. Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge. Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL Virology; 1992 Sep; 190(1):233-9. PubMed ID: 1529531 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins. Martin S; Cantin E; Rouse BT J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783 [TBL] [Abstract][Full Text] [Related]
14. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201 [TBL] [Abstract][Full Text] [Related]
15. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections. Soleimanjahi H; Roostaee MH; Rasaee MJ; Mahboudi F; Kazemnejad A; Bamdad T; Zandi K FEMS Immunol Med Microbiol; 2006 Feb; 46(1):100-6. PubMed ID: 16420602 [TBL] [Abstract][Full Text] [Related]
16. Expression of glycoprotein D of herpes simplex virus type 1 in a recombinant baculovirus: protective responses and T cell recognition of the recombinant-infected cell extracts. Krishna S; Blacklaws BA; Overton HA; Bishop DH; Nash AA J Gen Virol; 1989 Jul; 70 ( Pt 7)():1805-14. PubMed ID: 2544667 [TBL] [Abstract][Full Text] [Related]
17. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease. Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants. Blacklaws BA; Krishna S; Minson AC; Nash AA Virology; 1990 Aug; 177(2):727-36. PubMed ID: 2164732 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Ghiasi H; Nesburn AB; Wechsler SL Vaccine; 1996 Feb; 14(2):107-12. PubMed ID: 8852405 [TBL] [Abstract][Full Text] [Related]
20. Suppression of delayed type hypersensitivity to herpes simplex virus type 1 following immunization with anti-idiotypic antibody: an example of split tolerance. Lathey JL; Martin S; Rouse BT J Gen Virol; 1987 Apr; 68 ( Pt 4)():1093-102. PubMed ID: 3033128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]